PEMETREXED MARKET ANALYSIS

Pemetrexed MarketSize and Trends

Global pemetrexed market size was valued at US$ 2,287.2 Million in 2022 and is expected to witness a CAGR of 2.2% over the forecast period (2022 – 2030).

Figure 1.Global Pemetrexed Market Share (%), by Distribution Channel, 2022

Increasing demand of hospital pharmacies due to 340b program boosts the growth of the market over the forecast period.

Increase in the demand of hospital pharmacies due to 340b program (Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients) drives the growth of the market over the forecast period. For instance, in November 2021, according to the reports published in Science direct, an online publishing database, reported that 340b hospitals provided a significantly higher average number of medication access services compared to non-340B hospitals, whereas a higher percentage of 340B hospitals reported providing the service compared to non-340B hospitals in the U.S. These services are known to improve access and quality of care for low income populations.

Global Pemetrexed Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals.

Increasing termination on ongoing clinical trials during covid-19 in oncology department hindered the growth of global pemetrexed market. For instance, in July 2020, according to the reports published by The European Federation of Pharmaceutical Industries and Associations, a trade association and lobbying organization, over 20% of global oncology trials were halted because of the pandemic, with breast, prostate and lung cancer trials impacted the most.

Moreover, in March 2020, the National Institute for Health Research (NIHR) in the U.K. decided to prioritize COVID-19 related trials and paused all other new or ongoing trials, as well as non-COVID laboratory-based medical research.

Figure 2. Pemetrexed Market Share (%), by Region, 2022

North America is expected to hold dominant position, owing to high prevalence of non-small cell lung cancer in the U.S

Increasing number of prevalence of non-small cell lung cancer in the U.S. drives the global pemetrexed market over the forecast period. For instance, American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) had been diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC, Non-small Cell Lung, (68%), stage IIIA NSCLC, Non-small Cell Lung Cancer (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).